ISTH DIC subcommittee communication on anticoagulation in COVID-19.
J Thromb Haemost
; 18(9): 2138-2144, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-641045
ABSTRACT
Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID-19, but stress the need for further trials in this area.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Blood Coagulation
/
Blood Coagulation Disorders
/
Coronavirus Infections
/
Betacoronavirus
/
Anticoagulants
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Thromb Haemost
Journal subject:
Hematology
Year:
2020
Document Type:
Article
Affiliation country:
Jth.15004
Similar
MEDLINE
...
LILACS
LIS